EBOS GROUP LIMITED (EBO)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

EBO

EBO - EBOS GROUP LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 2.84
Index: ASX200 | ASX300 | ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$25.54

22 Sep
2025

0.610

OPEN

$25.51

2.45%

HIGH

$26.08

246,169

LOW

$25.30

TARGET
$31.94 25.1% upside
Franking for last dividend paid out: 95%
OTHER COMPANIES IN THE SAME SECTOR
ACL . AHX . ALC . BMT . DOC . HLS . IDX . M7T . MDR . MPL . MVF . NHF . PSQ . RHC . SHL .
FNARENA'S MARKET CONSENSUS FORECASTS
EBO: 1
Title FY24
Actual		 FY25
Actual		 FY26
Forecast		 FY27
Forecast
EPS (cps) xxx 109.7 135.4 xxx
DPS (cps) xxx 112.9 107.6 xxx
EPS Growth xxx - 22.4% 23.4% xxx
DPS Growth xxx N/A - 4.7% xxx
PE Ratio xxx N/A 18.9 xxx
Dividend Yield xxx N/A 4.2% xxx
Div Pay Ratio(%) xxx 102.9% 79.4% xxx

Dividend yield today if purchased 3 years ago: 3.34%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 4.53

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 29/08 - ex-div 49.71c (franking 49%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx109.7
DPS All xxxxxxxxxxxxxxx112.9
Sales/Revenue xxxxxxxxxxxxxxx12,266.9 M
Book Value Per Share xxxxxxxxxxxxxxx1,348.0
Net Operating Cash Flow xxxxxxxxxxxxxxx418.5 M
Net Profit Margin xxxxxxxxxxxxxxx1.75 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx8.29 %
Return on Invested Capital xxxxxxxxxxxxxxx5.70 %
Return on Assets xxxxxxxxxxxxxxx3.07 %
Return on Equity xxxxxxxxxxxxxxx8.29 %
Return on Total Capital xxxxxxxxxxxxxxx10.08 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx156.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx82 M
Long Term Debt xxxxxxxxxxxxxxx1,540 M
Total Debt xxxxxxxxxxxxxxx1,622 M
Goodwill - Gross xxxxxxxxxxxxxxx2,245 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx184 M
Price To Book Value xxxxxxxxxxxxxxx2.64

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx146.0 M
Capex % of Sales xxxxxxxxxxxxxxx1.19 %
Cost of Goods Sold xxxxxxxxxxxxxxx11,346 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx497 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx95 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.6

No. Of Recommendations

5
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Citi

xx/xx/xxxx

3

xxxxxxx xx xxxxxxx xxxx xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

xx/xx/xxxx

2

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

29/08/2025

2

Accumulate

$34.82

36.34%

Ebos Group's FY25 underlying profit missed Morgans' forecast with competitive pricing weighing on earnings (EBITDA) margins, down -3bps to 4.7%.

The results were weak, comments the broker, with net profit after tax down -21% on FY24, largely due to restructuring and the loss of the Chemist Warehouse contract.

Conversely, underlying performance was viewed as solid with robust results from Community Pharmacy, Terry White Chemmart and Animal Care.

FY26 guidance was the big miss and disappointment. Management is targeting earnings (EBITDA) growth of 7.5% at the midpoint, well below consensus expectations of 11%-12% growth, and this relates to more conservative pricing assumptions for wholesale.

Morgans lowers its net profit after tax forecasts by -15.5% for FY26 and -17.3% for FY27.

Target lowered to $34.82 from $39.15. No change in Accumulate rating. There is a high probability the stock will join the ASX200 in the September rebalance, the report states.

FORECAST
Morgans forecasts a full year FY26 dividend of 110.00 cents and EPS of 130.00 cents.
Morgans forecasts a full year FY27 dividend of 114.00 cents and EPS of 144.00 cents.

Macquarie

xx/xx/xxxx

1

xxxxxxxxxx

-

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

UBS

xx/xx/xxxx

1

xxx

-

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Jarden

10/09/2025

2

Overweight

-

-

Jarden notes FY25 marked a reset year for Ebos Group with earnings impacted by the loss of Chemist Warehouse Australia contract, competitive pharmacy pressures, and higher costs from the renewal of distribution centres.

The company expects headwinds to persist through 1H26, with leverage and PBS momentum benefits emerging in FY27.

The broker highlights Animal Care remained a steady performer (around 21% underlying EBITDA), with Next Gen and SVS adding future growth options. SE Asia Medical Devices (Transmedic) delivered strong growth and continues to offer bolt-on M&A opportunities.

Overweight. Target unchanged at $39, as the broker sees FY26 as a transitional year with long-term growth and ROCE momentum resuming from FY27–28.

FORECAST
Jarden forecasts a full year FY26 dividend of 97.00 cents and EPS of 129.60 cents.
Jarden forecasts a full year FY27 dividend of 103.00 cents and EPS of 147.20 cents.
Access Extra Coverage Research History >

EBO STOCK CHART

FNArena News on EBO

1
Weekly Ratings, Targets, Forecast Changes – 19-09-25

Sep 22 2025 - Weekly Reports
2
Australian Broker Call *Extra* Edition – Sep 10, 2025

Sep 10 2025 - Daily Market Reports
3
Rudi’s View: August Results; Standouts, Turnarounds, Failures & Misfits

Sep 10 2025 - Rudi's View
4
Australian Broker Call *Extra* Edition – Sep 04, 2025

Sep 04 2025 - Daily Market Reports
5
Rudi’s View: A Glass Half-Full Outlook

Sep 03 2025 - Rudi's View

Latest Healthcare services News

1
Better Times Ahead For Sonic Healthcare?

Jun 20 2025 - Australia
2
The Significance Of Cosmetique’s ASX Listing

Feb 26 2025 - Small Caps
3
Building The No 3 Diagnostic Imaging Player

Jun 19 2024 - Small Caps
4
Capitol Health’s Higher Margin Outlook

Mar 13 2024 - Small Caps
5
Treasure Chest: Ramsay Health Care

Oct 26 2023 - Treasure Chest
6
Timing Seems Right For Alcidion Group

Jun 21 2023 - Small Caps
7
No Enthusiasm To Combine ACL & Healius

Mar 21 2023 - Australia
8
Dr Boreham’s Crucible: Alcidion

Dec 13 2022 - Small Caps
9
No Straight Covid-Relief For Ramsay Health Care

Nov 15 2022 - Australia
10
Dr Boreham’s Crucible: Mach7 Technologies

Nov 14 2022 - Small Caps